Clinical Trial

APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational Reaserch

Recruiting
View on ClinicalTrials.gov →
Summary
APOLLO 11 main aim is to build a strong Italian long-lasting lung cancer network (in around 48 Italian centres) on real world data and translational research by creating a decentralized long-term national database (settle locally in each centre) and a "virtual" multilevel biobank in each centre. Besides, APOLLO 11 will take advantage of the translational research joint effort with the credo "unity is strength".
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-09-19.
Status change: Not Yet Recruiting → Recruiting 2023-10-17
Trial Details
NCT Number NCT05550961
Lead Sponsor Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Collaborators: Politecnico di Milano, Ospedale Policlinico San Martino, Insieme per i Pazienti di Oncologia Polmonare Onlus (IPOP), ASST Grande Ospedale Metropolitano Niguarda, University of Campania Luigi Vanvitelli, Azienda Ospedaliera dei Colli, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Ospedaliera S. Maria della Misericordia, Azienda Ospedaliera "Sant'Andrea", Azienda Ospedaliero Universitaria, Santa Maria della Misericordia di Udine, Italy, IRCCS Sacro Cuore Don Calabria di Negrar, Azienda Ospedaliero, Universitaria Ospedali Riuniti, Istituto Clinico Humanitas, Azienda Unità Sanitaria Locale della Romagna, Istituti Ospitalieri di Cremona
Conditions NSCLC, Cancer, Lung Cancer, Adenocarcinoma of Lung, Squamous Cell Lung Cancer
Enrollment 1,200 participants
Start Date 2022-10-01
Primary Completion 2027-10-01 (estimated)
Study Completion 2032-10-01 (estimated)
Updated on ClinicalTrials.gov 2023-10-23